Loading…
Employees: 14,846
Size China Traditional Chinese Medicine (0570.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $771M, the 661st largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$1.20 on 6 Nov 2026.
Performance Over six months the shares fell 29.4%, against -9.5% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 15.8% over the last twelve months (peer median +3.4%); the operating margin is 0.0% (peer median 9.2%).
Valuation It trades at 0.4× enterprise value to sales against a peer median of 2.4× (cheapest of 19).
Capital Return on invested capital runs 6.9 points below its cost of capital (6.9% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$14.2B | HK$16.0B | HK$17.9B | HK$20.0B | HK$16.6B |
| Revenue growth | — | -11% | -11% | +20% | — |
| Gross profit | HK$6.73B | HK$7.69B | HK$8.52B | HK$10.2B | HK$8.37B |
| EBITDA | HK$1.25B | HK$1.58B | HK$1.95B | HK$2.50B | HK$2.47B |
| Net income | -HK$1.14B | -HK$371M | HK$58.6M | HK$1.42B | HK$889M |
| Free cash flow | HK$1.63B | HK$1.67B | HK$2.84B | HK$1.25B | HK$43.6M |
| Capital expenditure | HK$296M | HK$352M | HK$555M | HK$540M | HK$613M |
| Total debt | n/a | HK$2.78B | HK$4.27B | HK$5.68B | HK$5.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0570.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -3.6% | 10th highest of 20 |
| 6-month return | -29.4% | -9.5% | 4th lowest of 20 |
| Distance from 52-week high | -50.0% | -32.1% | 4th lowest of 20 |
| Revenue growth (TTM) | -15.8% | +3.4% | 3rd lowest of 19 |
| Operating margin | 0.0% | 9.2% | 5th lowest of 19 |
| EV / Sales | 0.4× | 2.4× | cheapest of 19 |
| ROIC minus cost of capital | -6.9 pp | +0.2 pp | 4th lowest of 18 |
| EV / EBITDA | 4.2× | 11.2× | cheapest of 10 |
| Net debt / EBITDA | -3.0× | -0.5× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | 0.6× | 4.9% | +5.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 7.3× | 33.8% | +19.8% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |